Saltar al contenido

Semaglutide heart signal meets FDA import and Medicare access shifts — September 24, 2026

24 de septiembre de 2026 · 9 min

Notas del episodio

Semaglutide researchers say SELECT’s heart benefit isn’t fully explained by weight loss, but the practical GLP-1 fight is still access, from FDA import restrictions and Medicare Bridge uptake to Novo’s pipeline and oral manufacturing plans. Ask your prescriber before changing treatment.

In this episode
  1. Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! — EurekAlert!

    Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! News Release 23-Sep-2026 # Weight loss alone does not explain lower heart disease for those on semaglutide image: Professor Helen Colhoun view more Credit: Helen Colhoun / European Society of Cardiology - The SELECT trial has already shown a 20% lower risk of heart disease for people with…

  2. China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended — BigGo

    # China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended Published: 2026-09-22T13:35:30+00:00 Source: finance.biggo.com (finance.biggo.com) Language: en ## Story # China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended - Published: 2026-09-22T13:35:30.000Z - Updated: 2026-09-22T13:36:42.000Z - Author: BigGo Editorial Team -…

  3. Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint — AllSci

    Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint # Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint Edited by Robert McTiernan· September 22, 2026· 2 min read Novo Nordisk's cagrilintide and semaglutide combination CagriSema delivered superior weight loss versus a lower dose of tirzepatide in type 2 diabetes and met its primary…

  4. 700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK — IBTimes UK

    700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK ## Zepbound and Foundayo lead the market as Lilly captures 7 out of 10 new Medicare patients By Stephanie Cruz Published 24 September 2026, 1:50 AM BST Seniors get their weight-loss jabs for a $50 (£37) monthly copay under Medicare's Bridge programme, while drugmakers cash in on a…

  5. Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing — Pharma Manufacturing

    Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing # Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity The Danish drugmaker plans to scale production capacity to supply oral obesity therapies to 15 million patients globally by the end of the decade. Greg Slabodkin Sept. 22, 2026 5 min read 6ab29f6e83303d83b9ca0b11 Novonordisk…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily wherever you listen. Feedback? Email [email protected].

Todos los episodios de GLP-1 Daily: Ozempic & Wegovy News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.